James Anderson

Stock price provided by Lang & Schwarz

Showing transactions by James Anderson in Alnylam Pharmaceuticals, Inc..

Quarter	Type	Shares before	Shares after	Change	Price range
2025-Q1	Sell	4M	3.7M	-383K	€214.60–€268.50
2024-Q4	Sell	4.9M	4M	-847K	€218.70–€278.90
2024-Q3	Sell	6M	4.9M	-1.1M	€217.70–€259.70
2024-Q2	Sell	6.6M	6M	-591K	€133.70–€231.60
2024-Q1	Sell	7M	6.6M	-344K	€132.20–€179.80
2023-Q4	Sell	8.2M	7M	-1.2M	€141.80–€175.80
2023-Q3	Sell	8.4M	8.2M	-229K	€159.80–€195.80
2023-Q2	Sell	8.6M	8.4M	-247K	€171.40–€191.00
2023-Q1	Sell	9.4M	8.6M	-769K	€170.88–€222.00
2022-Q4	Sell	9.5M	9.4M	-107K	€187.92–€226.65
2022-Q3	Sell	10M	9.5M	-454K	€136.76–€227.45
2022-Q2	Sell	10M	10M	-171K	€114.11–€155.22
2022-Q1	Sell	11M	10M	-477K	€112.80–€153.40
2021-Q4	Buy	10M	11M	+201K	€134.15–€179.55
2021-Q3	Buy	10M	10M	+191K	€142.10–€177.65
2021-Q2	Buy	10M	10M	+150K	€105.70–€148.70
2021-Q1	Buy	9.1M	10M	+943K	€102.90–€144.14
2020-Q4	Buy	8.9M	9.1M	+241K	€103.22–€125.58
2020-Q3	Buy	8.6M	8.9M	+243K	€103.08–€145.20
2020-Q2	Buy	8.4M	8.6M	+237K	€95.98–€138.38
2020-Q1	Buy	8.2M	8.4M	+225K	€79.71–€123.02
2019-Q4	Sell	8.2M	8.2M	-49K	€68.45–€111.58
2019-Q3	Buy	6.2M	8.2M	+2M	€62.58–€78.96
2019-Q2	Buy	5.7M	6.2M	+529K	€59.02–€82.16
2019-Q1	Buy	4.7M	5.7M	+938K	€62.98–€82.60
2018-Q4	Buy	4.5M	4.7M	+284K	€54.94–€76.83
2018-Q3	Buy	4.2M	4.5M	+231K	€75.93–€104.81
2018-Q2	Buy	3.8M	4.2M	+398K	€74.69–€92.05
2018-Q1	Buy	3.6M	3.8M	+223K	€89.23–€121.99
2017-Q4	Buy	3.4M	3.6M	+206K	€95.71–€118.19
2017-Q3	Sell	3.4M	3.4M	-26K	€60.42–€99.89
2017-Q2	Buy	3.3M	3.4M	+97K	€44.36–€76.13
2017-Q1	Buy	3.3M	3.3M	+16K	€34.38–€54.53
2016-Q4	Sell	3.4M	3.3M	-50K
2016-Q3	Sell	3.4M	3.4M	-22K
2016-Q2	Buy	3.4M	3.4M	+10K
2016-Q1	Buy	2.7M	3.4M	+652K
2015-Q4	Buy	709K	2.7M	+2M
2015-Q3	Sell	792K	709K	-83K
2015-Q2	Sell	1M	792K	-232K
2015-Q1	Sell	1.1M	1M	-70K
2014-Q4	Sell	1.2M	1.1M	-98K
2014-Q2	Buy	1.1M	1.2M	+118K
2014-Q1	Buy	893K	1.1M	+180K
2013-Q4	Buy	753K	893K	+140K
2013-Q3	Sell	901K	753K	-148K

Transactions may be incomplete if the investor has purchased shares of the company before they reached the threshold for reporting set in the Securites Exchange Act or other applicable laws.

← Back to all investors